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While I share Dr. Mosley’s skepticism at some of the recent hope for 3-hydroxy-3-methyl-
glutaryl-CoA reductase inhibitors (statins) as treatment for non-vascular illnesses, I disagreed 
with his assertion that lipid levels should not be evaluated in the emergency department. Though 
Dr. Mosley’s cynicism regarding pharmaceutical companies’ influence on research findings may 
be well founded1, it should be pointed out that large, independently funded studies showing the 
mortality benefit of lipid reduction2 and lipid reduction specifically by statins3 in high-risk 
populations have been in the literature since the 1980s. 
When a statin-naïve patient presents with chest pain, his or her cardiovascular risk cannot be 
evaluated fully without knowledge of lipid status, a position endorsed by the National 
Cholesterol Education Program.4  The point that low-risk patients may not benefit from statin 
therapy is moot until all the relevant data are known.  Young people with heterozygous familial 
hypercholesterolemia, a common condition whose mortality can be reduced with cholesterol-
lowering therapy, present to physicians every day complaining of chest discomfort. 
In people already prescribed statins, compliance, even among high-risk patients, is poor.5  Beside 
directly questioning the patient, a method whose poor reliability is highlighted by the recent 
national movement toward “medication reconciliation”, adherence can be judged in only one 
way:  calculation or direct measurement of the serum low-density lipoprotein (LDL) level.  
Calculation of the LDL can be problematic because, as Dr. Mosley points out, a non-fasting 
specimen may be incalculable secondary to high serum triglyceride content.  If the patient is non-
fasting, though, the “non-HDL” cholesterol level serves as a suitable alternative.6  In the near 
future, measurement of the LDL level likely will be replaced by measurement of apolipoprotein 
B, which will eliminate the need for a fasting specimen.7 
While it is true that the immediate post-myocardial infarction effect of statin therapy has not 
lived up to its initial promise, the long-term effect of statins on mortality in high-risk populations 
is so profound, roughly a 1% decrease in five-year mortality for every 1 mg/dl reduction in LDL 
in high risk groups4, that adherence to therapy must be evaluated. 
Hypercholesterolemia is one of the primary modifiable risk factors for cardiovascular death.  A 
lipid panel, fasting or not, is a relatively inexpensive test that aids in risk-stratification of patients 
presenting with chest pain, helps evaluate compliance in people already prescribed statins, and is 
indispensable to the patient’s primary care provider, hospitalist, cardiologist, or endocrinologist. 
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